Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPAVmed Inc

PAVmed Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
1.82 USD -0.09 ( 4.71%)
Last update at 2026-11-03T21:00:00Z
VOLUME
12075
Market Cap
15.85M

Momentum Score

…

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.82
Low
1.98
High
52 Week Price Range
1.57
Low
9.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

PAVmed Inc develops and seeks to commercialize minimally invasive medical devices for office- and hospital-based procedures across multiple clinical areas. Long-term growth may be driven by regulatory approvals, reimbursement expansion, clinician adoption and strategic partnerships that could support commercialization, while a multi-product portfolio provides exposure to several addressable markets.

Key risks include clinical and regulatory setbacks, limited commercial revenue and recurring financing needs that may dilute shareholders, plus competition from larger device makers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.91
Dividend Yield
-
Revenue TTM
3.02M
Revenue Per Share
0.39
Gross Profit TTM
-3.24M
Debt / Equity
-0.91
ROE
-1358.06%
Net Debt
29.09M
ROCE
431.79%
Diluted EPS TTM
-9.00

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -103.24M -56.13M -35.89M -17.27M -18.17M
Minority interest 14.26M 5.78M -2.37M -0.81M -0.16M
Net income -101.29M -50.35M -34.33M -15.93M -17.97M
Selling general administrative 41.04M 25.57M 12.39M 7.66M 6.31M
Selling and marketing expenses 19.32M 8.89M - - -
Gross profit -3.24M -0.09M - - 0.00M
Reconciled depreciation 2.46M 0.23M 0.02M 0.01M 0.01M
Ebit -90.93M -54.39M -23.35M -14.30M -12.08M
Ebitda -92.80M -54.17M -23.99M -15.39M -12.07M
Depreciation and amortization -1.88M 0.23M -0.64M -1.09M 0.01M
Non operating income net other - -1.73M -12.54M -2.97M -7.61M
Operating income -90.93M -54.39M -23.35M -14.30M -10.56M
Other operating expenses 91.30M 54.89M 23.35M 14.30M 10.56M
Interest expense 1.27M 5.78M 0.05M 0.03M 2.39M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income - - - 0.59M 5.59M
Net interest income -1.27M 0.00M -0.71M -0.58M -3.01M
Income tax expense -1.94M -5.78M -1.56M -1.34M -0.20M
Total revenue 0.38M 0.50M 0.00M 0.00M 0.00M
Total operating expenses 87.69M 54.31M 23.35M 14.30M 10.56M
Cost of revenue 3.61M 0.58M - - 0.00M
Total other income expense net -12.31M -1.73M -12.54M -2.97M -4.60M
Net income from continuing ops -103.24M -56.13M -35.89M -17.27M -18.17M
Net income applicable to common shares -89.26M -50.63M -34.56M -16.73M -18.75M
Preferred stock and other adjustments - - - - 0.03M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 33.12M 53.98M 86.98M 19.78M 7.24M
Intangible assets 1.42M 3.44M 2029.00M - -
Other current assets 3.78M 3.90M 0.53M 0.85M 328284.00M
Total liab 57.14M 43.05M 7.56M 20.25M 11.88M
Total stockholder equity -53.83M -9.68M 61.67M 1.90M -3.82M
Other current liab 6.63M 3.71M 4.26M 0.05M 1.39M
Common stock 0.01M 0.10M 0.09M 0.06M 0.04M
Capital stock 3.00M 2.79M 2.50M 2.60M 2.34M
Retained earnings -294.43M -228.17M -138.91M -88.28M -53.71M
Good will - - -2026.97M - -
Other assets 0.00M 1.12M 0.72M 0.84M 0.69M
Cash 19.64M 39.74M 77.26M 17.26M 6.22M
Total current liabilities 54.18M 41.20M 7.56M 19.95M 11.88M
Current deferred revenue - - - 2.27M -
Net debt 29.09M -3.11M -77.26M -2.30M 1.92M
Short term debt 45.77M 34.79M - 14.66M 8.14M
Short long term debt 44.20M 33.65M - 14.66M 8.14M
Short long term debt total 48.73M 36.64M - 14.96M 8.14M
Other stockholder equity 3230.60M 215.70M 198.07M 87.57M 47.55M
Property plant equipment - 5.49M 1.58M 0.08M 0.69M
Total current assets 24.50M 43.93M 82.64M 18.94M 6.55M
Net tangible assets - -15.82M 57.22M -0.64M -6.12M
Short term investments 2.67M - - - -
Net receivables 0.06M 0.02M 0.20M - -
Long term debt - - - 0.30M -
Inventory 1.02M 0.26M 4.65M 0.85M -
Accounts payable 1.79M 2.70M 3.30M 2.97M 2.35M
Noncontrolling interest in consolidated entity - - 17.75M -2.37M -0.81M
Accumulated other comprehensive income -2993.00M - - - -
Common stock total equity - - 0.09M 0.06M 0.04M
Preferred stock total equity - - 2.42M 2.54M 2.30M
Retained earnings total equity - - -138.91M -88.28M -53.71M
Non currrent assets other 1.15M 1.12M 0.72M 0.84M 0.69M
Non current assets total 8.62M 10.05M 4.34M 0.84M 0.69M
Capital lease obligations 4.53M 2.99M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.74M -3.72M -0.06M -0.03M -0.03M
Change to liabilities -0.74M 2.09M 0.50M 0.67M 1.50M
Total cashflows from investing activities -4.74M -3.72M -0.06M -0.03M -0.03M
Net borrowings 35.23M -14.82M 16.70M 6.21M -5.00M
Total cash from financing activities 38.21M 104.31M 33.01M 11.38M 15.50M
Change to operating activities -0.16M -1.54M -0.42M -0.68M 0.47M
Net income -103.24M -56.13M -35.89M -17.27M -18.17M
Change in cash -37.51M 60.00M 11.04M -2.00M 6.69M
Begin period cash flow 77.26M 17.26M 6.22M 8.22M 1.54M
End period cash flow 39.74M 77.26M 17.26M 6.22M 8.22M
Total cash from operating activities -70.98M -40.59M -21.91M -13.36M -8.79M
Issuance of capital stock 1.89M 117.02M 16.03M 5.55M 4.41M
Depreciation 2.46M 0.23M 0.02M 0.01M 0.01M
Other cashflows from investing activities - -2.25M - - -
Dividends paid - 436.00M 0.36M 67436.00M 0.01M
Change to account receivables 0.18M -0.20M -0.20M -0.20M -0.20M
Sale purchase of stock -0.37M 436.00M 0.36M 67436.00M 16.44M
Other cashflows from financing activities 36.69M 2.26M 17.57M 6.20M -0.34M
Change to netincome 16.26M 15.14M 12.26M 1.57M 2.73M
Capital expenditures 1.54M 1.47M 0.06M 0.03M 0.03M
Change receivables - -0.20M - - -
Cash flows other operating - -1.73M 10.49M 1.66M -13.03M
Cash and cash equivalents changes - 60.00M 11.04M -2.00M 6.69M
Change in working capital -0.72M -1.57M 0.08M -0.06M 1.35M
Stock based compensation 19.53M 15.01M 2.04M 1.57M 1.23M
Other non cash items 10.98M -1.55M 5.33M 0.56M 3.10M
Free cash flow -72.53M -42.06M -21.97M -13.38M -8.81M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PAVM
PAVmed Inc		 -0.09
4.71%		 1.82 - - 7.22 7.42 20.30 -0.66
ABT
Abbott Laboratories		 -
-%		 109.40 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -0.41
0.41%		 98.88 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 3.74
1.22%		 310.55 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.66
1.38%		 48.35 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

PAVmed Inc

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

360 Madison Avenue, New York, NY, United States, 10017

212 949 4319

https://www.pavmed.com

107

Name Title Year Born
Dr. Lishan Aklog M.D. Chairman & CEO 1966
Mr. Dennis M. McGrath CPA Pres, CFO & Corp. Sec. 1957
Dr. Brian J. deGuzman M.D. Chief Medical Officer & Exec. VP of Clinical Affairs 1965
Mr. Shaun M. O'Neill M.B.A. Exec. VP & COO 1982
Mr. Adrian K. Miller VP of Investor Relations NA
Mr. Dennis M. McGrath CPA President, CFO & Corporate Secretary 1957
Mr. Shaun M. O'Neill M.B.A. Executive VP & COO 1983
Dr. Brian J. deGuzman M.D. Executive VP, Chief Technology & Compliance Officer 1965
Dr. Suman M. Verma M.D., Ph.D. Senior VP of Molecular Genetics & Chief Scientific Officer NA
Michael Parks Vice President of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…